Bristol Myers Squibb Co. (BMY)
67.66
+0.74
(+1.11%)
USD |
NYSE |
Sep 02, 16:00
67.58
-0.08
(-0.12%)
After-Hours: 20:00
Bristol Myers Squibb Cash from Investing (Quarterly) : -1.614B for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.614B |
| March 31, 2026 | -131.00M |
| December 31, 2025 | -1.458B |
| September 30, 2025 | -1.702B |
| June 30, 2025 | -473.00M |
| March 31, 2025 | -499.00M |
| December 31, 2024 | -196.00M |
| September 30, 2024 | -219.00M |
| June 30, 2024 | -1.319B |
| March 31, 2024 | -19.62B |
| December 31, 2023 | -1.346B |
| September 30, 2023 | -410.00M |
| June 30, 2023 | -329.00M |
| March 31, 2023 | -210.00M |
| December 31, 2022 | 1.213B |
| September 30, 2022 | -2.081B |
| June 30, 2022 | -289.00M |
| March 31, 2022 | 95.00M |
| December 31, 2021 | 401.00M |
| September 30, 2021 | -976.00M |
| June 30, 2021 | 180.00M |
| March 31, 2021 | -143.00M |
| December 31, 2020 | -12.13B |
| September 30, 2020 | -165.00M |
| June 30, 2020 | 780.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 653.00M |
| December 31, 2019 | -12.04B |
| September 30, 2019 | 491.00M |
| June 30, 2019 | 715.00M |
| March 31, 2019 | 1.06B |
| December 31, 2018 | -336.00M |
| September 30, 2018 | -147.00M |
| June 30, 2018 | -348.00M |
| March 31, 2018 | -43.00M |
| December 31, 2017 | 1.019B |
| September 30, 2017 | 142.00M |
| June 30, 2017 | -1.024B |
| March 31, 2017 | -203.00M |
| December 31, 2016 | 16.00M |
| September 30, 2016 | -368.00M |
| June 30, 2016 | 406.00M |
| March 31, 2016 | 1.426B |
| December 31, 2015 | -984.00M |
| September 30, 2015 | -62.00M |
| June 30, 2015 | -1.28B |
| March 31, 2015 | 754.00M |
| December 31, 2014 | 351.00M |
| September 30, 2014 | 164.00M |
| June 30, 2014 | -1.511B |
| March 31, 2014 | 2.212B |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -1.11B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
| Pfizer Inc. | 2.106B |
| AstraZeneca PLC | -1.856B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.393B |
| Cash from Financing (Quarterly) | -2.63B |
| Free Cash Flow | 11.44B |
| Free Cash Flow Per Share (Quarterly) | 1.508 |
| Free Cash Flow to Equity (Quarterly) | 4.464B |
| Free Cash Flow to Firm (Quarterly) | 3.418B |
| Free Cash Flow Yield | 8.27% |